A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Small Cell Lung Cancer Extensive Stage Clinical Trial

— TAXIO  

Official title:

A Phase II Study Assessing the Efficacy of Etoposide Free Chemotherapy Plus Durvalumab (MEDI4736) in First Line Extensive Disease Small Cell Lung Cancer (SCLC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05856695
• Other study ID #: IFCT-2203
• Status: Recruiting
• Phase: Phase 2
• Start date: November 17, 2023
• Est. completion date: February 2028

Study information

• Verified date: December 2023
• Source: Intergroupe Francophone de Cancerologie Thoracique
• Contact: Contact IFCT
• Phone: +33 1.56.81.10.45
• Email: contact[@]ifct.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The current study is intended to be a "proof of concept" to evaluate the potential value of synergy between paclitaxel carboplatin and immunotherapy. If a signal clearly shows superiority over the CASPIAN data , we will have arguments to think that the combination of paclitaxel and carboplatin is more suitable for synergy with immunotherapy than the standard etoposide and carboplatin.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 67
• Est. completion date: February 2028
• Est. primary completion date: February 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed Informed consent.

2. Patients diagnosed with histologically confirmed SCLC

3. Extended-Stage Disease at time of accrual according to the criteria of the Veteran's Administration Lung Cancer Group (VALG).

4. At least one measurable target lesion according to RECIST v1.1 per investigator assessment. The radiological assessment has to be done within the timelines indicated.

5. Age = 18 years.

6. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 (see Appendix 1).

7. Body weight >30 kg.

8. Adequate biological functions.

9. Woman patients who are no longer likely to procreate (physiologically unfit to carry a pregnancy), which includes: Hysterectomy, Ovariectomy, Bilateral tubal ligation, Postmenopausal women.

Woman patients who are of childbearing potential are eligible:

• They must have a negative serum pregnancy test within the week preceding the first dose of treatment and preferably as close as possible to the first dose.
• They must agree to use methods of contraception acceptable for IFCT. Contraceptive methods should be used throughout the course of treatment and should be maintained for 6 months after the end of treatment.

10. Male subjects who are sexually active with a woman of childbearing potential are eligible if an efficacious contraception method should be used during the treatment and during the 6 months following the last dose.

11. Patient must have a life expectancy of at least 12 weeks.

12. Patient covered by a national health insurance.

Exclusion Criteria:

1. Non-small cell lung cancer (NSCLC) or combined SCLC and NSCLC.

2. Prior systemic anticancer therapy for SCLC.

3. Radiotherapy needed at initiation of treatment.

4. Major surgical procedure (as defined by the Investigator) within 28 days prior initiation of treatment.

5. Symptomatic brain metastasis.

6. History of leptomeningeal carcinomatosis.

7. Symptomatic congestive heart failure, uncontrolled hypertension, unstable angina, cardiac arrhythmia or clinically uncontrolled heart disease.

8. Mean QT interval corrected (QTc) =470 ms.

9. Corticosteroid therapy at a dose greater than 10 mg per day of prednisolone or equivalent for more than 10 days within 14 days prior initiation of treatment.

10. Serum sodium <125 mmol/L unless corrective treatment prior to initiation of study treatment.

11. Hypercalcemia despite corrective treatment (corrected calcemia = Calcium (mmol) + [(40-albumin (g)) x 0.025]).

12. History of allogenic organ transplantation.

13. Immunosuppressive systemic therapy (cyclophosphamide, aziathioprine, methotrexate, thalidomide and TNF inhibitor) within 28 days prior to inclusion.

14. Active or prior documented autoimmune disease or inflammatory disorders including but is not limited to inflammatory bowel disease (colitis or Crohn's disease), diverticulitis (with the exception of diverticulosis), sarcoidosis syndrome, myasthenia gravis, lupus erythematosus, rheumatoid arthritis, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain Barré's syndrome, multiple sclerosis, vasculitis and glomerulonephritis.

Note: The following are exceptions are listed below:

• patients with vitiligo or alopecia,
• patients with history of autoimmune hypothyroidism treated with a stable dose of hormone replacement therapy,
• any chronic skin condition that does not require systemic therapy,
• patients without active disease in the last 5 years may be included but only after consultation with the investigator,
• patients with celiac disease controlled by diet alone,
• patients with diabetes treated with insulin.

15. Serious chronic gastrointestinal conditions associated with diarrhea

16. History of idiopathic pulmonary fibrosis, organized pneumonia (i.e., bronchiolitis obliterans), drug-induced pulmonary pathology or active signs of pneumonia, interstitial lung disease (whatever the cause) detected on the pulmonary CT-scan.

17. History of cancer Note: Patients with a history of cancer for more than 3 years are eligible if they have been treated and considered cured. Patients with a history of basal cell carcinoma of the skin or in situ carcinoma of the cervix are eligible.

18. Concomitant anti-cancer treatment or within 3 years prior to the start of study treatment, including chemotherapy, immunotherapy, hormone therapy, biotherapy or anti-angiogenic treatment (VEGF inhibitors or VEGFR inhibitors).

19. Any medical or personal that would make the patient unable to comply with study procedures and/or could interfere with the patient safety.

20. Receipt of live, attenuated vaccine within 30 days prior to the first dose of study drugs. Note: Patients, if enrolled, should not receive live vaccine whilst receiving study drugs and up to 30 days after the last dose of study drugs. Nucleic acid vaccines, inactivated vaccines against COVID-19 are allowed.

21. Ongoing or active infection including:

• COVID-19.
• Tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and tuberculosis testing in line with local practice).
• Hepatitis B virus (known positive HBV surface antigen [HbsAg] result). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HbsAg) are eligible.
• Positive hepatitis C virus (HCV).
• Human immunodeficiency virus (positive HIV 1 / 2 antibodies). Note: patients with severe psoriasis (10% of your body's surface area) are not eligible.

22. Paraneoplastic syndrome (PNS) of autoimmune nature, requiring systemic treatment (systemic steroids or immunosuppressive agents) or clinical symptomatology suggesting worsening of PNS.

23. Pregnant or lactating woman.

24. Known allergy or hypersensitivity to study treatment or any excipient.

25. Concomitant treatment with another experimental treatment or participation in another clinical trial.

26. Patient who is subject to legal protection or who is unable to express his will.

Related Conditions & MeSH terms

• Lung Neoplasms
• Small Cell Lung Cancer Extensive Stage
• Small Cell Lung Carcinoma

Intervention

Drug:
• Carboplatin + Paclitaxel + Durvalumab
Carboplatin AUC 6, day 1 of three-week cycle for four cycles Paclitaxel 200 mg/m² day 1 of a three-week cycle for four cycles Durvalumab 1500 mg every 3 weeks for 4 cycles followed by 1500 mg maintenance every 4 weeks until progression, unacceptable toxicity, or consent withdrawal

Locations

Country	Name	City	State
France	Abbeville - CH	Abbeville
France	Amiens - Clinique de l'Europe	Amiens
France	Angers - CHU	Angers
France	Besançon - CHU	Besançon
France	Bordeaux - CHU	Bordeaux
France	Boulogne - Ambroise Paré	Boulogne-Billancourt
France	Chambéry - CH	Chambéry
France	Cholet - CH	Cholet
France	Colmar - CH	Colmar
France	Annemasse - CH	Contamine-sur-Arve
France	Créteil - CHI	Créteil
France	Dijon - CHU Bocage	Dijon
France	Grenoble - CHU	Grenoble
France	Le Mans - CHG	Le Mans
France	Lyon - URCOT	Lyon
France	Marseille - APHM	Marseille
France	Marseille - Hôpital Européen	Marseille
France	Morlaix - CH	Morlaix
France	Orléans - CHR	Orléans
France	Paris - Bichat	Paris
France	Paris - Hôpital Cochin	Paris
France	Paris - Tenon	Paris
France	Rennes - CHU	Rennes
France	Toulon - Sainte Anne HIA	Toulon
France	Tours - CHU	Tours
France	Vandoeuvre-lès-Nancy - CRLCC	Vandœuvre-lès-Nancy
France	Villefranche sur Saône - CH	Villefranche-sur-Saône

Sponsors (1)

Lead Sponsor	Collaborator
Intergroupe Francophone de Cancerologie Thoracique

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Survival (OS)	Overall Survival (OS) defined as the time from the date of first dose of study drug to the date of death due to any cause	At 12 months
Secondary	Best response rate (RECIST 1.1)	Best response rate (RECIST 1.1) which is defined as the percentage of subjects with a complete response (CR) or partial response (PR) determined by Investigator review and by independent reviewer as per RECIST v1.1 criteria.	About 48 months
Secondary	Overall Survival (OS)	Overall Survival (OS) defined as the time from the date of first dose of study drug to the date of death due to any cause	About 48 months
Secondary	Overall Survival (OS)	Overall Survival (OS) defined as the time from the date of first dose of study drug to the date of death due to any cause	At 24 months
Secondary	Overall Survival (OS)	Overall Survival (OS) defined as the time from the date of first dose of study drug to the date of death due to any cause	At 36 months
Secondary	Progression free survival (PFS)	Progression free survival (PFS) defined as the time from the date of inclusion to the earliest date of disease progression, as determined by Investigator review and by independent reviewer of radiographic disease assessments per RECIST v1.1, or death due to any cause	About 48 months
Secondary	Safety and tolerability of paclitaxel carboplatin and durvalumab.	Incidence, nature, and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0)	About 48 months
Secondary	Quality of life of patients	Change from baseline of Quality of life assessment using European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30 LC13) at all scheduled time points.	About 48 months